[Science News] Ancient Fossils Link Complex Life to Oxygen (9.27)

2026-09-27 science science news 2026-09-27 science news 2026-09-27 sources science news 2026-09-27 summary 과학 과학 뉴스

Ancient Fossils Link Complex Life to Oxygen (9.27)

Overview
Details

Overview

More than 12,000 fossils from ancient Australian rocks appeared in oxygenated settings, adding evidence that early complex cells depended on oxygen.
In a 15-person Phase 1 trial, the highest dose of an experimental CRISPR treatment lowered LDL cholesterol by 52.5% after one year.
A health-record analysis linked glucosamine use to a 25% higher likelihood of progression from mild cognitive impairment to dementia, without establishing cause.
A simplified laboratory method measured DNA-bound phosphorus across 32 soil types, offering researchers another way to study nutrient cycling.

Details

Australian Fossils Place Early Complex Cells in Oxygenated Waters

An examination of ancient Australian rocks found more than 12,000 microscopic fossils identified as early eukaryotes, researchers reported in a study published in Nature. Eukaryotes are organisms whose cells contain a nucleus; animals, plants and fungi belong to this group. As ScienceDaily reported, the fossils came from rocks recording habitats that ranged from coastal mudflats to the open sea.

The distinction lay in the ancient water conditions. The researchers found the eukaryote fossils in samples deposited where oxygen was present. Samples from oxygen-free settings contained simpler microbial forms instead. They assessed those conditions using the chemistry of the rocks surrounding the fossils, alongside microscopic examination of the remains.

That pairing of fossils and environmental evidence makes the finding more informative than a fossil count alone. It connects the organisms to the waters in which they lived. The study supports a role for oxygen in the early history of complex cells, though it cannot identify the event that first produced them.

Key takeaway: The fossils connect some of the oldest known eukaryotes with oxygenated habitats, while leaving the origin of those cells unresolved.

Small CRISPR Trial Finds Blood-Fat Reductions Last One Year

A single infusion of an experimental gene-editing treatment produced blood-fat reductions that persisted for one year in a 15-person Phase 1 trial. At the highest dose, participants' LDL cholesterol fell 52.5% from baseline, while triglycerides fell 47.8%. LDL is often called “bad” cholesterol because elevated levels are associated with cardiovascular disease. ScienceDaily reported that the findings appeared in the New England Journal of Medicine.

The treatment, CTX310, uses CRISPR-Cas9, a tool designed to make targeted changes to DNA. It targets a liver gene called ANGPTL3, which helps regulate fats circulating in the blood. The trial enrolled people whose lipid disorders had not responded adequately to medication. Its purpose at this early stage was to assess safety and track biological effects, not to establish that the treatment prevents heart attacks or strokes.

Researchers reported no serious adverse events related to the therapy during the one-year follow-up. That is useful early safety evidence, but 15 participants cannot reveal every uncommon or delayed problem. The reductions also describe the highest-dose group; they should not be read as the expected result for everyone who might receive CTX310.

Key takeaway: CTX310's blood-fat effect lasted through one year of observation, but this small early trial cannot establish long-term safety or cardiovascular benefit.

Glucosamine Records Show Dementia Link, Not Proof of Harm

People with mild cognitive impairment who reported taking glucosamine were more likely to progress to dementia in a University of Florida health-record analysis. The reported association was 25% higher after researchers accounted for age, sex and demographic factors. Mild cognitive impairment means measurable changes in memory or thinking that do not necessarily disrupt everyday activities. ScienceDaily's September 27 account described the research, which was published in Nature Metabolism.

The investigators also studied brain tissue and mice to examine a possible biological explanation. Their work focused on excess attachment of sugar structures to proteins, a process that may affect how cells function. Those experiments make the question worth testing, but they do not establish that taking a glucosamine supplement causes dementia to advance in people.

The human result comes from existing records, rather than a trial that assigned people to take glucosamine or a comparison treatment. Differences between supplement users and nonusers may therefore have influenced the finding. The researchers say a controlled clinical trial is needed to test whether the supplement itself changes the course of disease.

Key takeaway: The records and laboratory findings justify further study, but they do not show that glucosamine causes dementia to progress.

Simpler Soil Test Tracks a Small, Active Phosphorus Pool

Researchers simplified a laboratory method for measuring phosphorus bound to DNA in soil and applied it to 32 soil types from the United Kingdom. Phosphorus is a nutrient plants need, while DNA-bound phosphorus may offer a window into the part of the soil nutrient cycle associated with living microbes. ScienceDaily reported that the method retained the precision and sensitivity needed for the measurements.

The team removed enzyme treatments it found unnecessary, reducing steps and cost. It kept ultrafiltration, which separates DNA-bound phosphorus from other phosphorus-containing material. That separation matters because measuring the wrong pool would weaken any conclusion about microbial activity.

The study, published in the Journal of Agricultural and Marine Sciences, concerns a research method rather than a new fertilizer practice. Better measurement could help investigators ask how microbes store and release nutrients. The reported results do not yet show that farmers can reduce fertilizer use or increase yields by applying the test.

Key takeaway: The revised test makes one biologically relevant phosphorus measure easier to obtain; its agricultural value depends on what further soil studies find.

In depth

Early eukaryote fossils — in depth

The question behind the study is whether early eukaryotes could occupy waters without oxygen. Most eukaryotes living today use oxygen, but some can survive without it. Present-day exceptions make it difficult to infer the needs of organisms that lived roughly 1.7 billion years ago. Fossils offer evidence from that earlier world, provided researchers can also reconstruct the conditions in which they were deposited.

The team worked with preserved drill cores from Australia's Northern Territory. After processing samples of mudstone, it examined the remaining organic material for fossils. The surrounding rock provided a separate line of evidence about the ancient seawater. Finding comparable organisms across several marine settings, while finding them only in oxygenated samples, strengthens the environmental association. It does not turn that association into a complete account of how complex cells evolved.

There is also a limit to what absence can show. Failure to find eukaryote fossils in the oxygen-free samples does not prove no such organisms lived anywhere without oxygen. Preservation varies between rocks, and a fossil survey samples only part of a vanished ecosystem. The result more directly describes where these researchers found the organisms in the rocks they studied.

The study's contribution is therefore a clearer picture of habitat. Oxygen may have helped early complex cells obtain the energy needed for their cellular organization. Testing how broadly that pattern applies will require fossils and environmental measurements from other ancient deposits. The distinction matters: evidence that oxygen shaped where early eukaryotes lived is narrower than proof that oxygen alone caused complex life to arise.

CRISPR cholesterol treatment — in depth

The appeal of targeting ANGPTL3 is that one intervention might produce a durable effect on two blood-fat measures. The trial's one-year results extend an earlier report made after two months. Persistence matters for a gene-editing treatment because the intended DNA change is lasting. The same feature makes long-term safety monitoring essential.

Dose is another important part of the finding. Participants received different amounts of CTX310, from 0.1 to 0.8 milligrams per kilogram of body weight. The roughly halved LDL and triglyceride measurements came from those at the highest dose. In a study this small, the dose-specific result cannot settle how consistent the effect would be in a larger or more varied group.

The two reported percentages refer to changes in laboratory measurements from participants' starting values. They do not mean cardiovascular risk fell by half. A larger trial would need to determine whether the biological effect remains reliable and whether it improves outcomes that matter to patients. It would also provide a better opportunity to detect safety problems that a 15-person study could miss.

According to the ScienceDaily account, researchers plan another 15 years of safety follow-up. That long horizon reflects a practical question raised by permanent editing: whether an apparently useful change remains safe well after the first year's blood tests. For now, the trial provides evidence of sustained lipid lowering in a small group, with clinical benefit still unproven.

Glucosamine and dementia — in depth

The study brings together two kinds of evidence that answer different questions. Health records can reveal a pattern among many patients, but they cannot by themselves explain what caused it. Laboratory work can probe a possible mechanism under controlled conditions, but results in mice or tissue cannot be assumed to predict a supplement's effect in humans. Reading both strands together gives a research hypothesis, not a clinical verdict.

The reported 25% is a relative comparison between groups in the records analysis. It does not mean one-quarter of glucosamine users developed dementia because they took it. The available account also does not establish an individual's chance of progression from that percentage alone. That distinction is especially important for a common supplement, where a broad claim of harm could travel much further than the evidence supports.

Researchers examined records collected from 2012 to 2024. About 8% of patients in the groups they studied reported glucosamine use. Such records depend on what was documented and cannot control supplement exposure in the way a randomized trial could. Adjusting for recorded characteristics helps address some differences between groups, but it cannot rule out every other explanation for the association.

The proposed sugar-tagging pathway offers a more precise question for future work: could glucosamine alter that process in a human brain already affected by disease? A clinical study would need to test that question while measuring cognitive outcomes and monitoring participants over time. Until then, the observation concerns an association in particular patient records, not a demonstrated effect of glucosamine on all older adults.

Soil phosphorus test — in depth

A soil's total phosphorus does not tell researchers how much is moving through living organisms. Some forms are held in material that changes slowly, while microbes continually take up and release nutrients. Measuring DNA-bound phosphorus could help distinguish activity in that biological pool from a broad total that combines many forms.

Simplifying the procedure has value only if it still identifies what it claims to measure. The team's two decisions illustrate that trade-off. Removing the enzyme treatments made the test easier to perform. Keeping ultrafiltration protected the distinction between DNA-bound phosphorus and other phosphorus compounds. The study therefore reports a narrower improvement than simply making every step faster.

Across the 32 soils, DNA-bound phosphorus made up a small share of organic phosphorus. Its concentration was related to several soil properties, including microbial biomass phosphorus, organic matter, acidity and phosphorus dissolved in soil water. Those relationships are consistent with a connection to living microbial processes. They do not show that one of those properties causes another to rise or fall.

The next practical question is whether the method helps researchers track changes across places, seasons or management practices. If it does, the resulting measurements could improve understanding of when phosphorus becomes available in soil. That would be a step toward more informed nutrient management, rather than evidence that a new farm practice is already effective.

At a glance

Fact	Publisher	Source
Researchers examined more than 12,000 fossils in ancient Australian rocks.	ScienceDaily	sciencedaily.com
Fossils identified as early complex cells occurred in oxygenated settings.	ScienceDaily	sciencedaily.com
A Phase 1 CRISPR trial followed 15 patients for one year.	ScienceDaily	sciencedaily.com
At the highest dose, LDL fell 52.5% and triglycerides fell 47.8% after one year.	ScienceDaily	sciencedaily.com
Glucosamine use was associated with a 25% higher likelihood of progression from mild cognitive impairment to dementia.	ScienceDaily	sciencedaily.com
Researchers applied a simplified phosphorus test to 32 soil types from the United Kingdom.	ScienceDaily	sciencedaily.com

FAQ

Q1. What did the fossil researchers actually test?

A. They compared microscopic fossils with evidence about the ancient waters recorded in the surrounding rocks. ScienceDaily reported more than 12,000 fossils and a pattern in which identified early eukaryotes appeared in oxygenated samples.

Q2. Why doesn't the CRISPR result establish a heart treatment?

A. The New England Journal of Medicine report described blood-fat measurements in a 15-person Phase 1 trial, according to ScienceDaily. Those measurements show a biological effect; this trial did not establish fewer heart attacks or strokes.

Q3. Does the glucosamine finding apply to everyone taking the supplement?

A. No. The 25% association came from health records of people with mild cognitive impairment, ScienceDaily reported. It does not measure the effect of glucosamine in all users, and the observational analysis cannot prove the supplement caused progression.

Q4. How does the soil method differ from a general phosphorus test?

A. It targets phosphorus bound to DNA, a small part of soil's organic phosphorus. ScienceDaily reported that researchers retained ultrafiltration to separate that material from other phosphorus compounds while removing enzyme steps they found unnecessary.

Q5. What evidence should come next?

A. The CRISPR researchers plan extended safety monitoring after their 15-person trial, while the glucosamine question needs a controlled human study. For the soil method, tests across additional conditions could show how useful its measurements are beyond the 32 United Kingdom soils.